‘Gray Market’ Retatrutide Study; Menopause and the Brain; Drug Allergy Warnings

People who took “gray market” compounded retatrutide, an investigational triple hormone receptor agonist, achieved less weight loss with up to 12 months of treatment than clinical trial participants, a preprint study suggested.

New York City sanitation workers said they are being pricked by improperly thrown-away injector pens for GLP-1 medications. (The Gothamist)

Strength training during pregnancy improved maternal quality of life but failed to reduce the incidence of gestational diabetes and related outcomes in a randomized trial of women with overweight. (Acta Obstetricia et Gynecologica Scandinavica)

A 17-year-old with diabetes died 24 days after being placed in a foster home not licensed to take him. (Missouri Independent)

The Departments of Veterans Affairs and Defense updated a joint obesity management guideline to emphasize flexible, individualized integration of pharmacotherapy and discourage discontinuing effective medications to prevent weight regain. (Annals of Internal Medicine)

Epic data suggested the rate of hormone therapy use among outpatient women nearly doubled in recent years, rising from 1.7% in January 2017 to 3.6% in April 2026, with progestin-only and estrogen-only products driving most of the growth.

Beyond aging, natural menopause was not linked to clinically meaningful changes in thyroid function, a Japanese cohort study found. (Journal of Clinical Endocrinology & Metabolism)

Longitudinal data showed that earlier age of menopause was associated with faster cognitive decline, earlier Alzheimer’s disease onset, and greater white matter hyperintensity accumulation. (JAMA Network Open)

Novo Nordisk is testing smaller doses of oral semaglutide for weight loss in its phase III OASIS 5 study, evaluating options below the currently approved 25 mg maintenance dose. (FiercePharma)

Vitruvias Therapeutics issued a nationwide recall of one lot of Thyroid Tablets, USP 30 mg, used to treat hypothyroidism, due to their potential to be superpotent, according to an FDA notice.

Parathyroid imaging should be conducted only when a primary hyperparathyroidism diagnosis is confirmed to avoid unnecessary radiation exposure, authors argued in JAMA Otolaryngology–Head & Neck Surgery.

New allergic reaction warnings were added to the labels of four osteoporosis drugs and one hypoparathyroidism drug earlier this month, a MedShadow report indicated.